A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

Megumi Kai1,2, Angela N. Marx1,2, Diane D. Liu3, Yu Shen3, Hui Gao2,4, James M. Reuben2,4, Gary Whitman2,5, Savitri Krishnamurthy2,6, Merrick I. Ross7, Jennifer K. Litton1, Bora Lim1,2,8, Nuhad Ibrahim1, Takahiro Kogawa1 & Naoto T. Ueno1,2,*

Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumorally at 10^6 PFU/mL on day 1 (cycle 1), 10^8 PFU/mL on day 22 (cycle 2), and 10^8 PFU/mL every 2 weeks thereafter (cycles ≥ 3). Nine patients were enrolled, 6 with only locoregional disease and 3 with both locoregional and distant disease. No patient completed the planned 10 cycles or achieved complete or partial response. The median number of cycles administered was 4 (range, 3–8). Seven patients withdrew prematurely because of uncontrolled disease progression, 1 withdrew after cycle 3 because of fatigue, and 1 withdrew after cycle 4 for reasons unrelated to study treatment. Median progression-free survival and overall survival were 77 days (95% CI, 63–NA) and 361 days (95% CI, 240–NA). Two patients received 8 cycles with clinically stable disease as the best response. The most common grade 2 or higher adverse event was injection site reaction (n = 7, 78%). Future studies could examine whether combining intratumoral T-VEC with concurrent systemic therapy produces better outcomes.

Following mastectomy or breast-conserving surgery, the 10-year incidence of locoregional breast cancer recurrence is about 12%1,2. Locoregional recurrence can result in substantial morbidity, and it also frequently leads to systemic metastases1–4. If the locoregional recurrence is locally limited, complete surgical resection and radiotherapy followed by systemic therapy can be considered depending on prior therapy3–8. However, if the locoregional recurrence manifests with diffuse skin disease, invasion into the surrounding structures, or advanced lymphadenopathy, disease is often inoperable. While systemic therapy is primarily indicated for patients with inoperable locoregionally recurrent breast cancer3,9, the treatment with multiple lines of systemic therapy increases the resistance of the disease, and the prognosis is typically poor. Therefore, there remains a strong need for new treatment modalities that will control locoregionally recurrent breast cancer effectively.

Talimogene laherparepvec (T-VEC) is an attenuated herpes simplex virus type 1 (HSV-1) that can replicate only in tumor cells10–14. T-VEC has been genetically modified to express GM-CSF to enhance the immune response by activating dendritic cells and stimulating T cells15,16. T-VEC is administered by direct injection into cutaneous or subcutaneous disease deposits and generates a systemic antitumor immune response. In a phase

---

1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030, USA. 2Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030, USA. 4Department of Hematopathology Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030, USA. 5Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030, USA. 6Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030, USA. 7Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030, USA. 8Present address: Department of Oncology/Medicine, Baylor College of Medicine, 7200 Cambridge St., Houston, TX 77030, USA. *Email: nueno@mdanderson.org
I trial in 2006, T-VEC was administered intratumorally in 30 patients with cancer in whom prior therapy had failed (14 with breast cancer, 9 with melanoma, 2 with colorectal cancer, and 5 with head and neck cancer). In this study, patients received either a single dose or 3 doses of T-VEC and were observed for 6 weeks after their last injection. T-VEC was well tolerated, and local inflammation, erythema, and febrile responses were the main side effects. Among the 14 breast cancer patients, 9 received a single dose, and 5 received 3 doses. Four of the breast cancer patients had local disease stabilization, but there were still issues controlling disease progression at non-injected lesions.

The purpose of the study we describe here was to determine the local and systemic antitumor efficacy of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer with or without distant metastases.

**Patient and methods**

This was a single-center, open-label, single-arm phase II study (ClinicalTrials.gov Identifier: NCT02658812). The protocol was approved by the institutional review board at The University of Texas MD Anderson Cancer Center. The study was conducted in accordance with the Declaration of Helsinki and adhered to Good Clinical Practice guidelines. All enrolled patients provided written informed consent.

**Eligibility.** To be eligible, patients had to have histologic confirmation of breast cancer recurrence with chest wall/cutaneous, subcutaneous, or nodal tumors with or without distant metastases. Patients also had to have at least 1 injectable lesion ≥ 5 mm in longest diameter or multiple injectable lesions with longest diameters totaling ≥ 5 mm. Furthermore, patients had to have received at least 1 systemic therapy regimen for the recurrent disease. An ECOG performance status of 0–1 and adequate organ function were required. Exclusion criteria included disease amenable to surgery with curative intent; metastatic sites that required urgent systemic chemotherapy; known active central nervous system metastases; > 3 lesions per organ in the case of visceral metastases other than lung or lymph node metastases; a history of prior complications from HSV-1 infection; and active autoimmune disease requiring systemic treatment.

**Treatment plan.** The trial was planned to conduct using a two-stage design, and the overall response rate was estimated accordingly. It was assumed that the T-VEC single agent would have a response rate of 20%. A 5% or lower response rate will be considered treatment failure, and the regimen will be rejected under this circumstance. 13 patients were planned to enroll in the first stage. If no patients achieve an overall response to the treatment, the trial will be stopped, and the regimen will be declared ineffective. If there are 1 or more patients achieve an overall response, 22 more patients will be enrolled to the study to reach a total of 35 treated patients.

Before administration of T-VEC, all patients underwent imaging and had baseline medical photographs taken to serve as references. T-VEC was injected into the visible sites of locally recurrent breast cancer or skin metastases on day 1 (cycle 1), day 22 (cycle 2), and every 2 weeks thereafter (cycles ≥ 3) until disease progression. The T-VEC concentration in the initial cycle was 10^6 PFU/mL, irrespective of HSV-1 serology status. The T-VEC concentration in the second and subsequent cycles was 10^8 PFU/mL. The total dose of T-VEC injected varied according to tumor size but did not exceed 4.0 mL in any injection cycle. Medical photographs of local lesions were taken before each cycle to record the extent of the disease. Imaging was planned for every 5 cycles until disease progression.

T-VEC was to be permanently discontinued if patients required another anticancer therapeutic agent for any reason, if therapy was delayed > 6 weeks because of a grade 2 or higher immune-mediated adverse event (AE)/allergic reaction, or if therapy was delayed > 4 weeks because of any other T-VEC-related grade 3 or higher toxicities. We designed the study to administer T-VEC for at least 10 cycles (approximately 5 months) unless uncontrolled disease progression was observed. Beyond 10 cycles, progressive disease will be measured based on RECIST ver1.1. Uncontrolled disease progression was defined as the rapid growth of multiple measurable or nonmeasurable new lesions or increase in the sum of the longest diameters of existing targeted lesions > 40% from the baseline. We chose 10 cycles of treatment because a previous study of intralesional T-VEC injections for advanced melanoma showed that more than half of the patients experienced pseudo-progression (an increase in the size of lesions or appearance of new lesions) before they achieved a response, with median time to response of 4.1 months.

**Toxicity assessment.** AEs and laboratory results were graded using the Common Terminology Criteria for Adverse Events, version 4.0. Grade 2 or higher nonhematologic AEs and grade 3 or higher hematologic AEs were recorded upon observation by the investigator or report by the patient regardless of whether the AEs were attributed to the investigational product. Grade 2 or higher abnormal laboratory values were recorded as AEs as well. Dose-limiting toxicities were defined as the following AEs when they were at least possibly related to T-VEC: herpetic event requiring treatment, grade 3 or higher immune-mediated AE, grade 2 or higher allergic reaction, grade 3 nonhematologic toxicity lasting more than 3 days, grade 3 or higher nonhematologic abnormal laboratory value failing to respond to medical intervention or leading to hospitalization, grade 2 or higher febrile neutropenia, grade 4 thrombocytopenia, and grade 4 nonhematologic toxicity. In the case of dose-limiting toxicity, T-VEC administration was deferred until the toxicity had resolved to at least grade 1 or returned to baseline levels.

**Endpoints.** The primary endpoint was the overall response rate, defined as the rate of patients who achieved a partial response or complete response as the best response for the measurable and nonmeasurable disease. The
response was planned to evaluate using RECIST version 1.1 at the end of cycle 10 and onward. Secondary endpoints were rates of local overall response/disease control rate, progression-free survival, and overall survival.

**Correlative immune studies.** Peripheral blood collected at baseline and before cycle 5 was analyzed to determine the subset of immune cells via multiparameter FACS (LSRII, BD Biosciences). We analyzed the percentage and absolute counts of total T cells (CD3+), helper T cells (CD4+), cytotoxic T cells (CD8+), B cells (CD19+), total NK cells (CD56+CD3−), NKT cells (CD56+CD3+), subset of NK cells (CD56+CD16+, CD56+CD16−, CD56−CD16+, CD56+CD57+), Treg cells, dendritic cells (DC), myeloid dendritic cells (mDC), and plasmacytoid dendritic cells (pDC). The paired t test was applied to compare between 2 time points.

**Statistical analysis.** Progression-free survival and overall survival from the date of treatment initiation were estimated using the Kaplan–Meier method with 95% confidence intervals (CIs). Progression-free survival was defined as the time from treatment initiation until disease progression, and overall survival was defined as the time from treatment initiation until death.

**Results**

**Patient characteristics.** Ten patients enrolled in the study, and 9 patients were treated in the study. Of the 10 patients who enrolled, 2 patients withdrew consent before initiating treatment to pursue alternate treatment; of these 2, one patient re-enrolled and received treatment on this study. Thus, 9 patients were evaluable for toxicity and response. The median age was 49 years (range, 39–70 years), and all of the participants had noninflammatory breast cancer. Six patients were seropositive and 3 were seronegative for HSV-1 at enrollment. Three patients had distant metastases in addition to locoregional disease (Table 1).

**Clinical response.** There were no complete or partial responses. None of the patients were able to complete the scheduled 10 cycles (Fig. 1); therefore, the study was discontinued prematurely without completing enrollment for the first stage. Median progression-free survival and overall survival were 77 days (95% CI, 63–NA) and 361 days (95% CI, 240–NA). The median number of cycles received was 4 (range, 3–8). In 7 patients (78%), the study treatment was discontinued because of uncontrolled disease progression. Among those 7 patients, 3

| Characteristic                  | n (%)                  |
|--------------------------------|------------------------|
| Age, median (range), y          | 49 years (39–70)       |
| Sex                            |                        |
| Female                         | 9 (100)                |
| Male                           | 0                      |
| Race                           |                        |
| White                           | 5 (56)                 |
| Black                           | 3 (33)                 |
| Asian                           | 1 (11)                 |
| Ethnicity                      |                        |
| Hispanic                       | 0                      |
| Not Hispanic                   | 9 (100)                |
| HSV-1 serology                 |                        |
| Positive                       | 6 (67)                 |
| Negative                       | 3 (33)                 |
| Type of breast cancer          |                        |
| IBC                            | 0                      |
| Non-IBC                        | 9 (100)                |
| Estrogen receptor status       |                        |
| Positive                       | 2 (22)                 |
| Negative                       | 7 (78)                 |
| Progesterone receptor status   |                        |
| Positive                       | 2 (22)                 |
| Negative                       | 7 (78)                 |
| HER2 status                    |                        |
| Positive                       | 1 (11)                 |
| Negative                       | 8 (89)                 |
| Distant metastases             |                        |
| No                             | 6 (67)                 |
| Yes                            | 3 (33)                 |

Table 1. Demographic and clinical characteristics at baseline. *IBC* inflammatory breast cancer.
patients had uncontrolled local disease, i.e., increase in tumor burden or appearance of new lesions; 2 patients developed new distant metastases; and 2 patients had both uncontrolled local disease and new or worsened distant metastases. Of the remaining 2 patients, I left the study after 4 cycles as she could not return to the clinic for reasons unrelated to study treatment, and 1 patient withdrew after 3 cycles because of fatigue (Fig. 1). These 2 patients had no images available to confirm the status of the local and the systemic disease at withdrawal.

The extent of chest wall/nodal disease at enrollment ranged from a solitary, well-defined lesion to grouped confluent lesions (Fig. 2). After treatment initiation, all patients reported local inflammatory reactions (erythema, edema, pain) at the injection sites, and 3 patients had necrosis in the tumor observed by physical examination. In 5 of the 9 patients, disease at the injection sites was clinically stable for a short period; lesions flattened and scabbed without local progression. The mean duration of this stabilization period was 21.8 days (range, 11–42 days). In the remaining 4 patients, there was no period of disease stabilization. No obvious differences in clinical response or toxicities were observed between HSV-1-seronegative and HSV-1-seropositive patients.

Toxicity. All 9 patients experienced at least 1 AE that was possibly related to the study drug. The most commonly reported grade 2 or higher AEs were grade 2 injection site reaction, defined as inflammation, erythema, or edema (n = 7); grade 2 injection site pain (n = 5); grade 2 fatigue (n = 4); grade 2 or 3 injection site infection (n = 3); and grade 2 or 3 lymphedema (n = 3) (Table 2). Of the 9 patients, 3 (33%) had a serious AE, defined as an event that necessitated hospitalization for > 24 h. Two patients were hospitalized for injection site infections, and 1 patient was hospitalized for fever.

Changes in immune phenotype in peripheral blood. There was no significant change in absolute lymphocyte count when we compared baseline and before cycle 5 (Fig. 3). However, the percentage of CD3+ and CD4+ decreased significantly before cycle 5 compared to baseline (p = 0.045 and p = 0.004, respectively, Fig. 4). Absolute count of CD4 was also significantly decreased (p = 0.027, not shown in Figure). In addition to subsets of T cells (i.e., CD3+ or CD4+ cells), CD56+CD57+ NK cells, which are the exhausted NK cells, were also significantly decreased (p = 0.049). Taken together, T-VEC indeed induced a response in a subset of systemic immune cells.

Discussion
T-VEC was approved by the U.S. Food and Drug Administration for the local treatment of unresectable lesions in patients with recurrent melanoma after initial surgery. This approval was based on the therapeutic benefit demonstrated in a phase III trial in patients with unresectable stage IIIB-IVM1c melanoma, in which T-VEC showed a 31.5% overall response rate with a 16.9% complete response rate14. In contrast, in the study we report here, T-VEC monotherapy provided unfavorable disease control in patients with inoperable locoregional recurrence of breast cancer. None of the patients in our study were able to complete 10 cycles of T-VEC as intended per protocol, mainly because of the increase in local tumor burden and/or occurrence of new distant metastases. However, it is worth noting that 1 patient who discontinued the study due to local progression exhibited a great response to concurrent radiotherapy and systemic therapy (immune checkpoint inhibitor and chemotherapy) immediately after this study (not mentioned in “Results”).

T-VEC has the potential to cause tumor lysis, which releases tumor-associated antigens, and GM-CSF, which T-VEC expresses, is a potent immune stimulator that enhances immune responses by activating dendritic cells and T cells to infiltrate the tumor15,16,19,20. A previous study showed that tumor-infiltrating lymphocytes in
Breast cancer are associated with better response to neoadjuvant chemotherapy; thus, intratumoral injection of T-VEC may generate a favorable tumor microenvironment to enhance response to chemotherapy. Indeed, a recent phase I trial of T-VEC combined with neoadjuvant chemotherapy for stage II–III triple-negative breast cancer showed a pathologic complete response rate of 55%, which was higher than the rate of 30–40% expected with neoadjuvant chemotherapy alone. T-VEC was injected intratumorally with intravenous paclitaxel up to 5 times, followed by doxorubicin/cyclophosphamide. Although the sample size was small (9 patients were treated), the results showed increases in cytotoxic T cell (CD8+) infiltration in most resected tumor bed specimens along with a reduction in regulatory T cells. These changes in the immune microenvironment of tumors also raised the possibility of further improvement in efficacy with checkpoint inhibitors, attracting significant interest in combination with T-VEC. Another phase I b study tested the combination of intrahepatic injection of T-VEC...
No dose-limiting toxicities were observed, and 1 patient had a partial response. The limitation of our analysis is that assessment of tumor tissues was not possible since none of the patients completed the study. Evaluation of alterations in the immune microenvironment of the injected and non-injected sites, including sites of distant disease, may provide valuable insights regarding the efficacy of T-VEC.

In conclusion, in patients with inoperable locoregional recurrence of breast cancer, intratumoral T-VEC as monotherapy was not therapeutically desirable owing to uncontrolled disease progression. In any future studies of this type of intratumoral immunotherapy for inoperable locoregional breast cancer recurrence, administration of concurrent systemic therapy would be warranted for an optimal outcome.

| Adverse event | Grade 2, n (%) | Grade 3, n (%) |
|---------------|---------------|---------------|
| General disorders and injection site conditions |               |               |
| Fatigue       | 4 (44)        |               |
| Fever         | 2 (22)        |               |
| Injection site reaction | 7 (78)        |               |
| Tumor/injection site pain | 5 (56)        |               |
| Gastrointestinal disorders |     |               |
| Constipation  | 1 (11)        |               |
| Nausea        | 2 (22)        |               |
| Vomiting      | 2 (22)        |               |
| Tumor/injection site infection | 1 (11)        | 2 (22)        |
| Myalgia       | 1 (11)        |               |
| Pain in extremity |     | 1 (11)        |
| Pruritus      | 1 (11)        |               |
| Lymphedema    | 2 (22)        | 1 (11)        |
| Neutrophil count decreased | 1 (11)        |               |

Table 2. Grade 2 or higher adverse events possibly, probably, or definitely related to T-VEC.

Figure 3. Changes in absolute lymphocyte count. BL baseline, C5D1 Cycle 5 Day 1, ns not significant. *One patient's sample was collected before Cycle 4.

T-VEC with intravenous atezolizumab in patients with triple-negative breast cancer with liver metastases. No dose-limiting toxicities were observed, and 1 patient had a partial response.

The limitation of our analysis is that assessment of tumor tissues was not possible since none of the patients completed the study. Evaluation of alterations in the immune microenvironment of the injected and non-injected sites, including sites of distant disease, may provide valuable insights regarding the efficacy of T-VEC.

In conclusion, in patients with inoperable locoregional recurrence of breast cancer, intratumoral T-VEC as monotherapy was not therapeutically desirable owing to uncontrolled disease progression. In any future studies of this type of intratumoral immunotherapy for inoperable locoregional breast cancer recurrence, administration of concurrent systemic therapy would be warranted for an optimal outcome.
Figure 4. Changes in percentage of immune phenotype. BL baseline, C5D1 Cycle 5 Day 1, ns not significant. *One patient's sample was collected before Cycle 4.

Received: 23 May 2021; Accepted: 5 October 2021
Published online: 15 November 2021

References

1. Clemons, M., Hamilton, T., Mansi, J., Lockwood, G. & Goss, P. Management of recurrent locoregional breast cancer: Oncologist survey. Breast 12, 328–337. https://doi.org/10.1016/s0960-9776(03)00107-3 (2003).
2. Clemons, M., Danson, S., Hamilton, T. & Goss, P. Locoregionally recurrent breast cancer: Incidence, risk factors and survival. Cancer Treat. Rev. 27, 67–82. https://doi.org/10.1053/ctrv.2000.0204 (2001).
3. Park, S. et al. Risk factors associated with distant metastasis and survival outcomes in breast cancer patients with locoregional recurrence. J. Breast Cancer 18, 160–166. https://doi.org/10.4048/jbc.2015.18.2.160 (2015).
4. Shenouda, M. N. et al. Clinical outcome of isolated locoregional recurrence in patients with breast cancer according to their primary local treatment. Clin. Breast Cancer 14, 198–204. https://doi.org/10.1016/j.clbc.2013.12.007 (2014).
5. Wapnir, I. L. & Khan, A. Current strategies for the management of locoregional breast cancer recurrence. Oncology (Williston Park) 33, 19–25 (2019).
6. Waerber, M. et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: Definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann. Oncol. 14, 1215–1221. https://doi.org/10.1093/annonc/mdg347 (2003).
7. Aebi, S. et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial. Lancet Oncol. 15, 156–163. https://doi.org/10.1016/s1470-2045(13)70589-8 (2014).
8. Network., N. C. C. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann. Oncol. 29, 1634–1657. https://doi.org/10.1093/annonc/mdy192 (2018).
10. Adair, R. A. et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. *Sci. Transl. Med.* 4, 138ra177. https://doi.org/10.1126/scitranslmed.3003578 (2012).

11. Shen, Y. & Nemunaitis, J. Herpes simplex virus 1 (HSV-1) for cancer treatment. *Cancer Gene Ther.* 13, 975–992. https://doi.org/10.1038/sj.cgt.7700946 (2006).

12. Muller, L., Berkeley, R., Barr, T., Ilett, E. &Errington-Mais, F. Past, present and future of oncolytic reovirus. *Cancers (Basel)* https://doi.org/10.3390/cancers12113219 (2020).

13. Andtbacka, R. H. I. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. *J. Clin. Oncol.* 33, 2780–2788. https://doi.org/10.1200/jco.2014.58.3377 (2015).

14. Andtbacka, R. H. I. et al. Final analyses of OPTIM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unrespectable stage III–IV melanoma. *J. Immunother. Cancer 7*, 145. https://doi.org/10.1186/s40425-019-0623-z (2019).

15. Kaufman, H. L., Ruby, C. E., Hughes, T. & Slingluff, C. L. Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. *J. Immunother. Cancer 2*, 11. https://doi.org/10.1186/s40425-014-0262-1 (2014).

16. Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. *Gene Ther.* 10, 292–303. https://doi.org/10.1038/sj.gt.3301885 (2003).

17. Hu, J. et al. A phase I study of OncoVEGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. *Clin. Cancer Res.* 12, 6737–6747. https://doi.org/10.1158/1078-0432.CCR-06-0759 (2006).

18. Website, U. S. F. a. D. A. IMLYGIC (talimogene laherparepvec). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic-talimogene-laherparepvec. Accessed in October 2020.

19. Conry, R. M., Westbrook, B., McKee, S. & Norwood, T. G. Talimogene laherparepvec: First in class oncolytic virotherapy. *Hum. Vaccines Immunother.* 14, 839–846. https://doi.org/10.1080/21645515.2017.1412896 (2018).

20. Parker, J. N. et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. *Proc. Natl. Acad. Sci.* 97, 2208–2213. https://doi.org/10.1073/pnas.040557897 (2000).

21. Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol.* 19, 40–50. https://doi.org/10.1016/S1470-2045(17)30904-X (2018).

22. Soliman, H. et al. A phase I trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer. *Clin. Cancer Res.* 27, 1012–1018. https://doi.org/10.1158/1078-0432.CCR-20-3105 (2021).

23. Dummer, R., Hoeller, C., Gruter, I. P. & Michielin, O. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. *Cancer Immunol. Immunother.* 66, 683–695. https://doi.org/10.1007/s00262-017-1967-1 (2017).

24. Hamid, O., Ismail, R. & Puzanov, I. Intratumoral immunotherapy—Update 2019. *Oncologist* 25, e423–e438. https://doi.org/10.1634/theoncologist.2019-0438 (2020).

25. Hecht, J. R. et al. Abstract P3–09–19: Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer. *Cancer Res.* 80, P3-09-19-P03-09-19. https://doi.org/10.1158/1538-7445.Sabcs19-p3-09-19 (2020).

Acknowledgements
The authors thank Stacy Moulder, Rashmi Murthy, and Abenaa Brewster for referring and enrolling patients in the trial and Stephanie Deming of the Research Medical Library at MD Anderson for editing assistance.

Author contributions
T.K. and N.T.U. conceived and designed the study. J.M.R. and S.K. assisted in designing the study. A.N.M., G.W., M.I.R., J.K.L., B.I., N.I. and N.T.U collected clinical data and patient samples. H.G. and J.K.L. analyzed the blood samples. D.D.L. and Y.S. performed the formal analysis. M.K., A.N.M. and N.T.U. wrote the first draft of the manuscript. All authors reviewed and edited the manuscript for submission.

Funding
Fundled by the NIH/NCI through the Cancer Center Support Grant of The University of Texas MD Anderson Cancer Center (CA016672); the Morgan Welch Inflammatory Breast Cancer Research Program; a State of Texas Rare and Aggressive Breast Cancer Research Program Grant; and Amgen Inc.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to N.T.U.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021